Despite trading at low multiples, Viatris is exposed to macroeconomic headwinds, regulatory pressures, and a $500M revenue hit from FDA actions, increasing downside risk. Recent impairments and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results